<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791201</url>
  </required_header>
  <id_info>
    <org_study_id>VX22-264-101</org_study_id>
    <nct_id>NCT05791201</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes</brief_title>
  <official_title>A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in&#xD;
      participants with type 1 diabetes (T1D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 1 up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B and Part C: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT)</measure>
    <time_frame>From Baseline and at Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part C: Change in peak C-peptide during MMTT</measure>
    <time_frame>From Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Change in Average Total Daily Insulin Dose</measure>
    <time_frame>From Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Proportion of Participants who are Insulin Independent at One Point in Time</measure>
    <time_frame>From Day 180 up to Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Change in HbA1c values</measure>
    <time_frame>From Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>VX-264</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-264</intervention_name>
    <description>Allogeneic human stem cell-derived islets.</description>
    <arm_group_label>VX-264</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Clinical history of T1D with greater than (&gt;) 5 years duration&#xD;
&#xD;
          -  Participant is on a stable diabetic treatment&#xD;
&#xD;
          -  Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before&#xD;
             Screening and willingness to use CGM for the duration of the study&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior islet cell transplant, organ transplant, or cell therapy&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 16, 2023</study_first_submitted>
  <study_first_submitted_qc>March 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 16, 2023</last_update_submitted>
  <last_update_submitted_qc>March 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

